EQRx International, Inc.
๐บ๐ธUnited States
Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer
Phase 3
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- EQRx International, Inc.
- Registration Number
- NCT05712941
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- EQRx International, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05493501
- Locations
- ๐บ๐ธ
Northwest Medical Specialties, PLLC, Tacoma, Washington, United States
๐บ๐ธQCCA - Mission Blood & Cancer, Des Moines, Iowa, United States
๐บ๐ธMemorial Cancer Institute, Pembroke Pines, Florida, United States
An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- EQRx International, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05199610
- Locations
- ๐บ๐ธ
Global Clinical Professionals, Saint Petersburg, Florida, United States
๐บ๐ธAmerican Institute Research, Los Angeles, California, United States
๐บ๐ธTexas Liver Institute, San Antonio, Texas, United States
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
- Conditions
- First Posted Date
- 2021-11-23
- Last Posted Date
- 2023-03-27
- Lead Sponsor
- EQRx International, Inc.
- Registration Number
- NCT05131438
- Locations
- ๐บ๐ธ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath